The Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine) has launched the NUS Medicine Protein Biomarker Discovery Core Facility, which will provide the Olink Explore 3072, Olink Explore 1536, Olink Target 96 and Target 48, and the recently launched Olink Flex platforms. These solutions for advanced protein biomarker research range from high-plex, high throughput discovery to more targeted biomarker studies. 

The Olink technology allows for high throughput screening and detection of large numbers of proteins in small amounts of biological samples, such as blood plasma and saliva, which could potentially be protein biomarkers for disease. 

Based at NUS Medicine, the core facility will support researchers and scientists from NUS and the industry, both locally and globally in their understanding of disease, as well as the effects and outcomes of treatment. This also empowers pharmaceutical companies to better understand the mode of action and dose selection of new drugs, and to follow up on their clinical trials.  

Another focus of the facility will be support of population health studies, which are gaining interest and attraction from the pharmaceutical industry globally. Singapore is uniquely placed with its diverse ethnicities and highly developed research infrastructure, as well as widespread global collaborations.

The core facility will be utilising the Olink technology for a broad range of projects in the fields of heart failure, stroke, diabetes, healthy aging, mother and child, cancer and infectious disease, as well as in large cohort studies. The technology will enhance patient stratification, better diagnosis and disease management, and supports novel drug development with the prospect of new tests and treatments which will benefit Singapore.